Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration

• Published in: International journal of molecular sciences Vol. 23; no. 18; p. 10257
• Main Authors: Wagener, Nele, Lehmann, Wolfgang, Weiser, Lukas, Jäckle, Katharina, Di Fazio, Pietro, Schilling, Arndt F., Böker, Kai O.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.09.2022; MDPI
• Subjects: Adrenergic receptors; Adult; Apoptosis; Atomoxetine Hydrochloride - pharmacology; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactivity disorder; Bone density; Bones; Cell adhesion & migration; Cell Differentiation; Central Nervous System Stimulants - pharmacology; Child; Chronic fatigue syndrome; Cognitive enhancement; Dopamine; Guanfacine - pharmacology; Humans; Ligands; Methylphenidate - therapeutic use; Modafinil - pharmacology; Modafinil - therapeutic use; Nervous system; Nootropic Agents - therapeutic use; Osteoprotegerin - therapeutic use; Receptor Activator of Nuclear Factor-kappa B; Stem cells; cell migration; ADHD; apoptosis; bone defect; hMSCs; osteogenic differentiation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms231810257

Attention deficit hyperactivity disorder (ADHD) is one of the most common worldwide mental disorders in children, young and adults. If left untreated, the disorder can continue into adulthood. The abuse of ADHD-related drugs to improve mental performance for studying, working and everyday life is also rising. The potentially high number of subjects with controlled or uncontrolled use of such substances increases the impact of possible side effects. It has been shown before that the early ADHD drug methylphenidate influences bone metabolism negatively. This study focused on the influence of three more recent cognitive enhancers, modafinil, atomoxetine and guanfacine, on the differentiation of mesenchymal stem cells to osteoblasts and on their cell functions, including migration. Human mesenchymal stem cells (hMSCs) were incubated with a therapeutic plasma dosage of modafinil, atomoxetine and guanfacine. Gene expression analyses revealed a high beta-2 adrenoreceptor expression in hMSC, suggesting it as a possible pathway to stimulate action. In bone formation assays, all three cognitive enhancers caused a significant decrease in the mineralized matrix and an early slight reduction of cell viability without triggering apoptosis or necrosis. While there was no effect of the three substances on early differentiation, they showed differing effects on the expression of osterix (OSX), receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) in the later stages of osteoblast development, suggesting alternative modes of action. All three substances significantly inhibited hMSC migration. This effect could be rescued by a selective beta-blocker (Imperial Chemical Industries ICI-118,551) in modafinil and atomoxetine, suggesting mediation via beta-2 receptor stimulation. In conclusion, modafinil, atomoxetine and guanfacine negatively influence hMSC differentiation to bone-forming osteoblasts and cell migration through different intracellular pathways.